Baker Bros. Advisors 13F: Cuts Immatics (IMTX) Stake by $12M

Baker Bros. Advisors Trims Position in Immatics N.V.

Baker Bros. Advisors pulled back on its investment in Immatics N.V. IMTX, according to the fund's Form 13F filing with the SEC for the period ending May 15, 2026. The prominent life-sciences investor cut its holdings by 1,177,401 shares, marking a 9.7% decrease from the prior period. After the adjustment, the firm owned 10,916,693 shares of the clinical-stage biotech company. That remaining stake held a reported value of about $110.58 million at the time of the filing.

How the Fund Adjusted Its Immatics Holdings

Prior to the reduction, Baker Bros. Advisors held 12,094,094 shares of Immatics. The sale of 1.17 million shares brought the total down to 10,916,693. Because 13F filings look backward at holdings from the end of the reporting period, these figures reflect past positioning and may not match the firm's current share count today.

Immatics Stock Context and Trading Levels

Immatics shares recently changed hands around $10.13. The stock has traded within a 52-week range of $6.86 to $12.41. Its 50-day moving average sits at $9.19, while the 200-day moving average rests near $9.93. The company carries a market capitalization of roughly $1.32 billion. Because the firm lost money over the past year, it has no meaningful P/E ratio.

Recent Insider Activity at Immatics

Insiders have also adjusted their holdings in the company. On June 16, 2026, Peter Alan Chambre acquired 48,000 shares of Immatics N.V.

Analysts Set New Price Targets

Wall Street firms continue to evaluate the biotech's prospects. On October 14, 2026, Stifel initiated coverage on the stock with a Buy rating and a $15.00 price target. Across the broader analyst community, the stock holds a consensus target price of $17.63 based on six analyst opinions.

Inside the Immatics Pipeline

Immatics N.V. is a clinical-stage biopharmaceutical company headquartered in Tübingen, Germany. The firm focuses on researching and developing T cell redirecting immunotherapies to treat cancer. Its pipeline features targeted treatments for solid tumors through adoptive cell therapies and antibody-like TCR bispecifics, including programs like Anzu-cel.

What to Watch Next for Immatics

Investors will want to watch for the company's next earnings report, scheduled for November 17, 2026, alongside any future SEC filings from major institutional holders like Baker Bros. Advisors to spot further shifts in ownership.